MDRD eGFR Calculator (4-Variable MDRD Study Equation)

About

The Modification of Diet in Renal Disease (MDRD) Study equation was developed in 1999 by Levey and colleagues from a cohort of 1,628 patients with chronic kidney disease who participated in the MDRD Study, a landmark clinical trial investigating the effects of dietary protein restriction and blood pressure control on CKD progression. The original equation required six variables including serum albumin and blood urea nitrogen. The simplified 4-variable version, published in 2000 and re-expressed in 2006 for standardized creatinine assays, uses only serum creatinine, age, sex, and race (Black versus non-Black). The MDRD equation was the first widely adopted estimating equation and transformed clinical practice by enabling routine GFR estimation without requiring 24-hour urine collections or exogenous filtration markers. It was validated in multiple populations, though its derivation cohort consisted predominantly of CKD patients with a mean measured GFR of approximately 40 mL/min/1.73m². Consequently, the MDRD equation performs well at lower GFR levels but systematically underestimates measured GFR in healthy individuals and those with eGFR ≥60 mL/min/1.73m², leading to overdiagnosis of CKD in the general population. Despite being largely supplanted by the CKD-EPI equation for general use, MDRD remains embedded in many clinical laboratory reporting systems, epidemiological studies, and clinical trials that require consistency with historical data. The equation includes a race coefficient of 1.212 for Black patients, which has been the subject of health equity concerns similar to those that led to the removal of race from CKD-EPI. Many laboratories in the United States have transitioned to reporting both MDRD and CKD-EPI values, with a gradual shift toward CKD-EPI as the preferred equation.

Formula

eGFR = 175 × (SCr)^-1.154 × (Age)^-0.203 × (0.742 if female) × (1.212 if Black)

The 4-variable MDRD equation computes eGFR in mL/min/1.73m² using the formula: eGFR = 175 × SCr^-1.154 × Age^-0.203 × (0.742 if female) × (1.212 if Black). Each component reflects a distinct physiological relationship. The serum creatinine term (SCr^-1.154) is an inverse power function — as creatinine rises, eGFR declines exponentially. The exponent -1.154 indicates a steep decline at lower creatinine values that plateaus somewhat at higher values. The age term (Age^-0.203) accounts for the physiological decline in GFR with aging, with the negative exponent reducing eGFR as age increases. The exponent -0.203 is smaller in magnitude than the creatinine exponent, indicating that age has a relatively modest effect compared to creatinine. The sex correction factor of 0.742 for females adjusts for the lower average muscle mass and consequently lower creatinine generation in women. Without this factor, women with equivalent renal function would have lower creatinine and therefore be incorrectly assigned a higher eGFR. The Black race factor of 1.212 was derived from observations that Black individuals have, on average, higher muscle mass and creatinine generation at equivalent measured GFR, and was intended to correct for this difference. However, this adjustment has been controversial due to concerns that it may mask reduced kidney function in Black patients. The equation uses standardized creatinine values (IDMS-calibrated) — non-standardized values require different coefficients (186 instead of 175 for the intercept). The result should be reported as eGFR in mL/min/1.73m². Values exceeding 60 mL/min/1.73m² should be reported as "≥60" because the equation is not sufficiently accurate above this threshold. Key limitations: the MDRD equation was derived from a cohort that was predominantly White (approximately 85%), had mostly advanced CKD (mean eGFR ~40), and included very few patients with diabetic nephropathy or transplant recipients. This limits its generalizability to primary care populations with preserved kidney function.

Score Interpretation

The MDRD Study equation revolutionized kidney disease assessment and remains historically important in nephrology. It was endorsed by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) in 2002 as part of the first clinical practice guidelines for CKD evaluation, and it enabled the transition from reporting only serum creatinine to reporting eGFR in clinical laboratories. This change dramatically increased CKD awareness and diagnosis worldwide. The MDRD equation served as the primary method for eGFR reporting in the US and many other countries from approximately 2005 through the 2010s. It has been used extensively in epidemiological studies such as the National Health and Nutrition Examination Survey (NHANES) to estimate the global burden of CKD. It also formed the basis for the KDIGO CKD classification system that combines eGFR categories (G1-G5) with albuminuria categories (A1-A3). Despite its widespread adoption, the MDRD equation has important limitations that influence clinical decision-making. Its systematic underestimation of GFR in healthy individuals — typically by 5-10 mL/min/1.73m² — can lead to falsely labeling healthy people as having CKD stage G2 or even G3a. Overdiagnosis carries consequences including unnecessary specialist referrals, increased health anxiety, and potential insurance implications. The CKD-EPI equation was specifically developed to address this bias and provides more accurate estimates at higher GFR levels. Contemporary guidelines from KDIGO, the American Diabetes Association, and the UK National Institute for Health and Care Excellence recommend CKD-EPI as the preferred equation, but acknowledge that MDRD remains acceptable when consistency with historical data is needed. Many laboratories still report MDRD eGFR alongside or in transition to CKD-EPI. For clinical trials and research studies, the choice between equations should be specified a priori, and switching equations within a longitudinal study should be avoided due to systematic differences of 5-10% between them.

Reference Ranges